Latest Breaking News On - Global medical affairs - Page 18 : comparemela.com

Gilead Sciences Presents Three-year Outcomes From BICSTaR Study With Biktarvy

Gilead Sciences Presents Three-year Outcomes From BICSTaR Study With Biktarvy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Fernando bognarIndiens wirtschaftIhre chancenGilead sciences incGilead sciencesMore such health newsGlobal medical affairsVice presidentDer indienDie highlights

EACS 2023: Gilead shares real-world evidence for Biktarvy®

EACS 2023: Gilead shares real-world evidence for Biktarvy®
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Fernando bognarMichael sabranskiMental health component summaryGilead sciencesStudy centerGlobal medical affairsGilead scienceBictegravir single tablet regimenVice president

VedaBio Launches with Over $40 Million to Revolutionize Molecular Detection

SAN DIEGO (BUSINESS WIRE) Oct 17, 2023

United statesChristine ginocchioFred sweeneyWill harrisKaren sharmaRavi vijayendranRashid bashirDon masquelierPhil belgraderAnurup ganguliMerieux biofireSally brashearGlobal medical affairsGrainger college of engineeringDrug administrationResearch program

Alexion Reveals C5 Inhibition Impact on NMOSD at MSMilan2023

Alexion Reveals C5 Inhibition Impact on NMOSD at MSMilan2023
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChristophe hotermansHead of global medical affairsResearch in multiple sclerosisOdense university hospitalAlexion pharmaceuticals incAmericas committee for treatmentMeeting of the european committee for treatmentAstrazeneca rare diseaseJoint meetingEuropean committeeMultiple sclerosisAmericas committeeSenior vice presidentGlobal medical affairs

AstraZeneca : Alexion data at 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) showcase impact of C5 inhibition in NMOSD -October 11, 2023 at 02:21 am EDT

Alexion, AstraZeneca Rare Disease, will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee.

United statesUnited kingdomChristophe hotermansOdense university hospitalResearch in multiple sclerosisHead of global medical affairsAlexion pharmaceuticals incMeeting of the european committee for treatmentAmericas committee for treatmentAstrazeneca rare diseaseJoint meetingEuropean committeeMultiple sclerosisAmericas committeeSenior vice presidentGlobal medical affairs